3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Poly (ADP-ribose) Polymerase Research

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a cell-permeable, nanomolar-potency inhibitor of poly (ADP-ribose) polymerase (PARP), achieving over 95% inhibition of PARP activity at concentrations above 1 μM in vitro with negligible cytotoxicity (APExBIO A4161). In Chinese hamster ovary (CHO) cell models, its IC50 is approximately 50 nM, supporting sensitive inhibition assays (Grunewald et al., 2019). The compound demonstrates robust solubility in water, ethanol, and DMSO, facilitating broad experimental workflows. It is widely used to dissect oxidant-induced myocyte dysfunction, endothelial nitric oxide signaling, and diabetic nephropathy mechanisms (related article). The product is distributed by APExBIO and is intended strictly for research use, not for clinical or diagnostic purposes.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of ADP-ribosyltransferases that catalyze the transfer of ADP-ribose units from NAD+ to target proteins, resulting in mono- or poly-ADP-ribosylation (Grunewald et al., 2019). Humans encode at least 17 PARPs, with PARP1 being the most abundantly expressed and a central mediator of DNA damage response and cellular stress signaling. ADP-ribosylation regulates chromatin structure, DNA repair, cell death, and innate immunity. Inhibition of PARP activity is used experimentally to block these signaling pathways and to study their physiological and pathological consequences. 3-Aminobenzamide (PARP-IN-1) selectively inhibits PARP enzymatic activity, enabling controlled modulation of these processes in cellular and animal models. The compound is particularly valued for its role in deciphering oxidant-induced tissue injury, endothelial dysfunction, and diabetic nephropathy pathogenesis (see comparative analysis). This article extends prior reviews by providing up-to-date, evidence-based usage guidelines and integration strategies for 3-Aminobenzamide (PARP-IN-1).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide acts as a competitive inhibitor of PARP enzymes, binding to the NAD+ binding site of the catalytic domain. This mechanism prevents the transfer of ADP-ribose units to acceptor proteins, thereby blocking both mono- and poly-ADP-ribosylation. The compound exhibits an IC50 of approximately 50 nM for PARP1 inhibition in CHO cells, and achieves >95% inhibition of PARP activity at concentrations above 1 μM (benchmark report). Notably, at these concentrations, 3-Aminobenzamide does not induce significant cellular toxicity or affect viability in most mammalian cell lines. Its selectivity allows for precise dissection of PARP-dependent processes, including DNA repair, oxidative stress responses, and inflammatory signaling. Importantly, 3-Aminobenzamide does not inhibit unrelated NAD+-utilizing enzymes under standard assay conditions, reducing off-target risks when used within recommended concentration ranges.

Evidence & Benchmarks

• 3-Aminobenzamide inhibits PARP1 activity with an IC50 of ~50 nM in CHO cell extracts (Grunewald et al., 2019).
• At ≥1 μM, 3-Aminobenzamide achieves >95% inhibition of total cellular PARP activity without significant cytotoxicity (APExBIO datasheet, product page).
• PARP inhibition by 3-Aminobenzamide enhances acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation following H₂O₂-induced oxidative stress (chempaign.net article).
• In diabetic db/db mice, 3-Aminobenzamide reduces albuminuria, mesangial expansion, and podocyte depletion, supporting its use in diabetic nephropathy research (anhydrotetracycline.com article).
• Pan-PARP inhibition, including by 3-Aminobenzamide, enhances viral replication and inhibits interferon production in primary macrophage models, confirming the regulatory role of PARPs in antiviral immunity (Grunewald et al., 2019).

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely used in the following applications:

• PARP activity inhibition assays: Standard tool for benchmarking PARP1 and PARP2 inhibition in mammalian cell and tissue models, including CHO cells (APExBIO).
• Oxidant-induced myocyte and endothelial dysfunction: Enables mechanistic studies of oxidative injury and nitric oxide signaling, with clear evidence in vascular smooth muscle and endothelium (chempaign.net).
• Diabetic nephropathy research: Used in preclinical db/db mouse models to probe diabetes-induced kidney damage, albuminuria, and podocyte loss (anhydrotetracycline.com).
• Innate immunity and viral pathogenesis: Applied in studies dissecting the interplay between PARP-mediated ADP-ribosylation and viral replication/interferon signaling (Grunewald et al., 2019).

Common Pitfalls or Misconceptions

• 3-Aminobenzamide is not selective for individual PARP isoforms and may inhibit multiple family members at experimental concentrations.
• The compound is not intended for diagnostic or clinical therapeutic use; it is strictly for research applications (APExBIO).
• Long-term storage of prepared solutions is discouraged due to potential degradation; fresh solutions are recommended for reproducibility.
• High concentrations (>1 mM) may lead to off-target effects or altered cell viability in sensitive lines; titration is recommended.
• PARP-independent processes may not be affected, and negative results do not rule out roles for other ADP-ribosyltransferases.

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1) is supplied as a solid by APExBIO (SKU A4161; product page). The molecular weight is 136.15 g/mol; chemical formula C₇H₈N₂O; CAS 3544-24-9. Recommended solubility is ≥23.45 mg/mL in water (ultrasonic assistance), ≥48.1 mg/mL in ethanol, and ≥7.35 mg/mL in DMSO. For maximum stability, store powder at -20°C and avoid repeated freeze-thaw cycles. Solutions should be prepared fresh and not stored long-term. Typical working concentrations for cellular PARP inhibition range from 0.1 μM to 1 mM, with >95% inhibition achieved at 1 μM in CHO cell extracts. For assay design and troubleshooting, see 'Scenario-Based Best Practices with 3-Aminobenzamide (PARP-IN-1)' (anhydrotetracycline.com), which details real-world usage scenarios and optimization strategies. This article extends those protocols by providing up-to-date solubility and storage data for enhanced reproducibility.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) remains a benchmark compound for poly (ADP-ribose) polymerase inhibition in both cellular and animal models. Its robust potency, low cytotoxicity, and favorable physicochemical properties enable its integration into diverse research workflows. As understanding of PARP biology expands, particularly in areas of oxidative injury, immune regulation, and metabolic disease, 3-Aminobenzamide—available from APExBIO—will continue to support high-fidelity, reproducible experiments. For the latest product data and ordering options, consult the A4161 product page.